Author response for 'Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: real world evidence from the Nordic EMPRISE study'
Autor: | null Thomas Nyström, null Emilie Toresson Grip, null Joel Gunnarsson, null Paula Casajust, null Kristina Karlsdotter, null Josefin Skogsberg, null Anastasia Ustyugova, null Moe H. Kyaw, null Maria Lajer, null Gitte Mateusen, null Lisette Koeneman, null Neus Valveny, null Emma Söreskog, null Riho Klement, null Fabian Hoti, null EMPRISE Study Group |
---|---|
Rok vydání: | 2022 |
Databáze: | OpenAIRE |
Externí odkaz: |